Angle Share News (AGL)

Technology firm incubator Angle saw an acute increase in its share price after one of its subsidiaries was granted a US patent.Angle's 83% owned medical diagnostics company Parsortix has been issued a US patent relating to its technology for particle and cell separation, identification, sorting and manipulation.It is the first in what is expected to be a series of United States and International patents for Parsortix's proprietary devices and methods for isolating cells from blood and other mixed cell suspensions. The company was keen to emphasise that these devices and methods can be used for a wide range of medical diagnostic applications including, for example, the isolation of disseminated or circulating tumour cells from cancer patient samples and the capture of a developing foetus' cells from a sample of its mother's circulating blood."Unlike many cell-separating technologies that rely on antibody binding, the Parsortix technology does not require target cells to express and display antibody-binding protein for separation and, as a result, substantially reduces problems sometimes associated with that approach such as the risk of false positives or false negatives," the company noted. The technology also enables further identification or characterisation through specialised analysis. Parsortix Chief Executive, Dr. Shane Booth, said the award of the patent "substantiates our technological and consequent commercial capability and will be the basis of product development activity with which we intend to solve significant barriers to clinical and research capability."The announcement spelt good news for the company, as the share price rose 10.42% to 26.50p at 12:23. NR